Evidence map›Paper›PMID 33564075›Full record

ArticleOncogene2021

Correction to: Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer.

Che-Pei Kung, Kyle A Cottrell, Sua Ryu, Emily R Bramel, Raleigh D Kladney, Emily A Bao, Eric C Freeman, Thwisha Sabloak, Leonard Maggi, Jason D Weber

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Che-Pei Kung *Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.ORCID http://orcid.org/0000-0002-1150-4998
Kyle A Cottrell *Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Sua RyuDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Emily R BramelDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Raleigh D KladneyDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Emily A BaoDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Eric C FreemanDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Thwisha SabloakDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Leonard MaggiDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA.ORCID http://orcid.org/0000-0003-0138-0984
Jason D WeberDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, MO, USA. jweber@wustl.edu.ORCID http://orcid.org/0000-0002-1069-6983

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33564075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.